Impaired FGF10 Signaling and Epithelial Development in Experimental Lung Hypoplasia With Esophageal Atresia

Jun Wang¹², Hao Liu¹, Linlin Gao³ and Xiaomei Liu¹

¹ Key Laboratory of Maternal-Fetal Medicine of Liaoning Province, Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China, ² Department of Obstetrics and Gynecology, Benxi Central Hospital of China Medical University, Benxi, China, ³ Central Laboratory, Shengjing Hospital of China Medical University, Shenyang, China

Patients with esophageal atresia (EA) and tracheoesophageal fistula (TEF) often experience persistent respiratory tract disease. In experimental models, doxorubicin-induced developmental lung abnormalities may result from downregulation of branching morphogenesis factor fibroblast growth factor (Fgf10). This study investigated the temporospatial expression of Fgf10 pathway components and lung epithelial factors in an doxorubicin-induced EA-TEF model by quantitative polymerase chain reaction, immunohistochemistry, and immunoblotting. Epigenetic regulation of gene expression by histone deacetylation was also investigated. Bone morphogenetic protein (Bmp) 4 and Cathepsin H (Ctsh), downstream targets of Fgf10, were significantly downregulated in the EA-TEF model during the saccular stage, consistent with Fgf10 expression. The developmental expression pattern of P2x7 receptor (ATI-cell marker), Sftpα, and Sftpβ in lung epithelial cells was not affected. Sftpα (ATII-cell marker) and Scgb1a1 (Clara cell marker) were significantly downregulated at the canalicular stage. Meanwhile, histone deacetylase (Hdac) 1 was upregulated and subsequently decreased acetylation of histone H3 Lys56 in the EA-TEF model, which returned to a normal level at the saccular stage. In conclusion, disturbed molecular signaling involving Fgf10/Ctsh was associated with impaired airway branching and epithelial cell development in lung morphogenesis, as evidenced by downregulated Sftpα and Scgb1a1 protein expression. The influence of Hdac1 activity on gene and protein expression in lung epithelial cells deserves further study.

Keywords: esophageal atresia, lung, Fgf10, Ctsh, epigenetic

INTRODUCTION

Esophageal atresia (EA) is the most frequent congenital anomaly of the esophagus, occurring in approximately one of every 4099 births worldwide [1]. Abnormal separation of the foregut into the esophagus and trachea during development results in lack of esophageal continuity with or without an abnormal connection of the esophagus and trachea and formation of a tracheo-esophageal fistula.
(TEF). Neonates with EA-TEF may have respiratory malformations, which are found in 2.88% of patients and in 13.2% of autopsies [2]. EA-TEF survivors often experience persistent nonspecific respiratory tract disease with chronic cough, asthma-like symptoms, recurrent pneumonia or bronchiectasis, and chronic bronchitis [3] that do not improve or become more frequent with age [4, 5]. Gastro-esophageal reflux, peptic bronchitis, post-thoracotomy chest wall deformities, or the fistula stump account for these long-term sequelae. Defects in the airway or lung parenchyma or lung hypoplasia may also be involved [6–8].

Rat lung development includes embryonic, pseudoglandular, canalicular, saccular, and alveolar stages. It is a highly regulated process directed by mesenchymal-epithelial interactions, which coordinate the spatiotemporal expression of multiple regulatory factors [9]. Due to the limited availability of lung tissue sample from human subjects, rodent model was applied to perform basic research. Doxorubicin (Adriamycin)-exposed fetal rats, has been widely used because of closely mimics the human phenotype, with up to 70% of tracheo-esophageal malformations [10, 11]. Deficient embryonal lung branching and lung hypoplasia in fetal rats with EA-TEF caused by doxorubicin exposure is accompanied by downregulated fibroblast growth factor 10 (Fgf10) at the saccular stage (E21) [12]. During lung development, signaling by Fgf10 and its epithelial tyrosine kinase transmembrane receptor, fibroblast growth factor receptor 2b (Fgfr2b), are required for coordinated induction of several genes that control proliferation, differentiation, and branching of the lung epithelial tubules [12]. Lungs formation does not occur in genetically modified mice in which Fgf10 or its receptor Fgfr2b have been deleted [13, 14]. Activation of Fgf10-Fgfr2b signaling has induces the expression of bone morphogenetic proteins in lung epithelium [15]. The study was designed to determine whether disruption of Fgf10 signaling induces defective branching morphogenesis in EA-TEF. The study objective was to assay spatiotemporal expression of Fgf10 signaling pathway participants and lung epithelial markers in a rat model of EA-TEF caused by intrauterine exposure to doxorubicin. The underlying epigenetic mechanism of changes of gene expression was also investigated.

MATERIALS AND METHODS

Animals

This study was carried out in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals recommended by Animal Research Committee of China Medical University. The protocol was approved by the Animal Research Committee of China Medical University. Rats weighing 230–260 g (Changsheng Biotechnology, Benxi, China) were housed individually at 21–22°C on a 12:12 h light-dark cycle. Timed-pregnant Wistar rats were bred in house, and the day that a vaginal plug was found was day 0. Doxorubicin -treated rats received three intraperitoneal injections of 1.75 mg/kg doxorubicin (Haizheng Pharmaceutical Co., Taizhou, China) in saline on embryonic days E7, E8, and E9 as previously described [10]. Control rats received an equivalent volume of saline on the same schedule. A subset of dams was killed by injection of potassium chloride on E15, E18, and E21. The chests of the fetus were dissected and whose trachea which was directly connected to the lung and stomach was considered to be esophageal atresia (Figure S1).

| Gene name | Accession number | Primer sequences | Size (bp) |
|-----------|------------------|------------------|-----------|
| Sph | NM_017221 | F: 5- AAAGCTGACCCCCCTTAGCCTA-3 | 103 |
| R: 5- TTGGAGGTTTCCTGGAATCTCC-3 |
| Fgfr2b | NM_001109896 | F: 5- ACGGACAAGAAAGACCCCTACAT-3 | 92 |
| R: 5- TGTCACATGACGGTAGCAAGGGTGA-3 |
| Cttsh | NM_012939 | F: 5- TTGCTATGGAGAAGAAGAAGA-3 | 96 |
| R: 5- CACGTCAAAGAGAGAAGAAGA-3 |
| Bmp4 | BC078901 | F: 5- CAGAGCCCCACACTGTGAGGAGGA-3 | 108 |
| R: 5- GGGATGCTGGCTGAGGATCTAAA-3 |
| Bmpr1a | S75359 | F: 5- GCCACCTTGGAACACACAGAGC-3 | 101 |
| R: 5- GCAAGCTGTGCTACAGGAG-3 |
| Bcl-2 | NM_016933.1 | F: 5- CCGGGAGGAGAGGATCGGATGATGAA-3 | 81 |
| R: 5- CCCAATCCTGAGGCCCCCCACCTCGT-3 |
| Bim | NM_022612 | F: 5- GAGAAGAGTTGACAAATTCACACG-3 | 91 |
| R: 5- CTCCTTGCTGGCTGAGGATCTAAA-3 |
| Sttfa | NM_001270645 | F: 5- TACAGAGCGAGAGAGGGAAAC-3 | 68 |
| R: 5- CAATCATTGCTAGTGCTGCTGAT-3 |
| Sttibo | NM_138842.1 | F: 5- CCATCCTGCTGCTGCTCTG-3 | 80 |
| R: 5- CACCTGGGAAATACAGAGTTGAT-3 |
| Sttpc | NM_017342.2 | F: 5- TCCAGGAGGCCATGTTGCC-3 | 61 |
| R: 5- CAGTGATAGGAGGGCCTGATGAT-3 |
| P2x7r | NM_019256.1 | F: 5- CAGTGGAAAAAGCGGCAATGTA-3 | 66 |
| R: 5- CCACTGGCCCAAAAAAACAGGAT-3 |
| Scgb1a1 | NM_130501.1 | F: 5- CGQACATCTGCACCGAGATTTCTC-3 | 208 |
| R: 5- ACAACAGGAGACTTTGAGATG-3 |
| Pla2g4a | NM_133551.2 | F: 5- GAAAGTTCCTGACTGCGACAGACTC-3 | 234 |
| R: 5- TTCTAGAGGGGCTTCTACACACC-3 |
| Pla2g2a | NM_031598.3 | F: 5- CCAGAAGAGAAGGCAACAGATT-3 | 200 |
| R: 5- TCTTGCGCGAAAACCTACG-3 |
| DNM_1-1 | NM_013062 | F: 5- AAGGAAGGAACTGCTCCTACACT-3 | 148 |
| R: 5- TCAGTCCGTAGCTGCTGCTC-3 |
| Hdac-1 | NM_001025409 | F: 5- CCTACCCGAATTCGAAATG-3 | 145 |
| R: 5- CAAATACAAAGGGAAGAAACTG-3 |
| Hdac-2 | NM_053447 | F: 5- TCAAGGGTTATCGACATAGAAGG-3 | 77 |
| R: 5- CTCTTCCGAGATTTAATCTCAG-3 |
| Hdac-5 | NM_053450 | F: 5- AAGCCAGGAGTAAAGCCAGAGGAGG-3 | 104 |
| R: 5- CCTCTGCTGGAAGGAAATCTTG-3 |
| β-actin | NM_031144.3 | F: 5- AGCTCTCTACGCTCCTCCTCAAAAAGG-3 | 97 |
| R: 5- AAGCAATGCTGCTACCTTCGCC-3 |

β-actin was used as the housekeeping gene.
The embryonic lungs were removed and dissected free from the trachea.

Morphometry
Immunohistochemical (IHC) staining of fixed lung tissue was performed as previously described [10]. After tracheal cannulation, 4% paraformaldehyde was injected at <10 cm/H2O for alveolar distention, the fetal lungs were collected, fixed in formalin, embedded in paraffin, and sectioned. Tissue sections were stained with hematoxylin and eosin for evaluation of general tissue morphology. IHC staining was performed on 3 µm serial sections using standard techniques. Briefly, after rehydration in a graded alcohol series, sections were boiled in 0.01 M sodium citrate for antigen retrieval prior to antibody incubation. Sections were incubated overnight with primary antibodies including rabbit polyclonal anti-Scgb1a1 (1:200, 26909-1-AP, Proteintech), anti-Pla2g4a (1:100, 10827-1-AP, Proteintech) and mouse monoclonal anti-histone deacetylase (Hdac1, 1:200, 10197-1-AP, Proteintech). Negative controls were included. Imaging at low (200 x) and high (400 x) magnification was taken on a Nikon ECLIPSE Ti microscope. All images were analyzed with NIS-Elements BR 2.10 image software (Nikon, Tokyo, Japan).

RNA Extraction and Quantitative PCR
Expression of Fgf10 signal-related factors, lung proximal and distal epithelium markers, and epigenetic regulation factors in fetal lung were assayed by quantitative PCR. Total RNA was

FIGURE 1 | Kinetics of Fgf10 signaling pathway factors in fetal lungs. (A–E) Shh, Fgf2b, Bmp4, Bmpr1a, and Shh mRNA expression was assayed by quantitative PCR in EA and control lungs during the pseudoglandular (E15), canalicular (E18), and saccular (E21) stages, and results are shown relative to controls at E15. Data are means ± SEM, *P < 0.05, EA-TEF vs. age-matched controls between group; #P < 0.05, E18 or E21 vs. E15 within group (each n = 6). Due to the huge difference between the values in the same chart, the error bars of some of the points are too small to display. The data of Shh- EA-TEF-E15 is 0.618 ± 0.031; the data of Fgfr2b- CON-E15 is 1.002 ± 0.032; the data of Bmpr1a- EA-TEF-E15 is 0.679 ± 0.059. (F) Representative 2% agarose gel electrophoresis images of the amplicon size and the specificity of PCR products.
extracted from snap-frozen lungs by Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s protocol, and the concentration was determined spectrophotometrically in duplicate (Nano Vue; GE Healthcare, Buckinghamshire, England). Reverse transcription and amplification were performed as previously described [16]. Amplification was performed with a LightCycler 480 SYBR Green I Master (Roche, Mannheim, Germany) in 20 µL of reaction solution with specific primers for target genes. Quantitative PCR was performed in multiple cycles using a 7500 Fast thermal cycler (ABI, Inc., USA) with denaturation at 94°C for 1min, annealing at 60°C for 50s, and elongation at 72°C for 0.5min. The specific primers and annealing temperature of each gene are listed in Table 1. The specificity of the PCR products was confirmed by analysis of the dissociation curve. The expected amplicon size, and the absence of nonspecific products were confirmed by analysis of the PCR products on 2% agarose gels, followed by ethidium bromide staining and visualization under UV light. The relative mRNA levels were calculated using the 2−ΔΔCt method after normalization against β-actin as a housekeeping gene.

Immunoblotting
Immunoblotting was used to assay target protein expression in the rat embryo lungs. Total protein was extracted from frozen lung tissue with RIPA lysis buffer following the kit manufacturer’s (P0013B, Beyotime, China) instructions. Histones were extracted from lung tissues using EpiQuik total histone extraction kits (EpiGentek Group Inc., Farmingdale, NY, USA). The protein concentration was measured with a bicinchoninic acid assay kit (Pierce Biotechnology, Waltham, MA, USA). Equal amounts of total protein were separated by electrophoresis on 6–12% sodium dodecyl sulfate polyacrylamide gel electrophoresis, depending on the molecular weights of the target proteins, and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, MA, USA) as described by Towbin et al. [17]. After blocking the PVDF membrane with 5% nonfat milk in Tween-20 containing Tris buffered saline for 2hr at room temperature, the blots were immunoprobed with rabbit polyclonal anti-Ctsh (1:400, Proteintech, China), anti-Hdac1 (1:800, Proteintech) and mouse monoclonal anti-β-actin (1:5,000, Proteintech) overnight at 4°C. The membranes were probed with a horseradish peroxidase-conjugated secondary antibody for 2hr at room temperature. The antigen-antibody complexes were visualized with an electrochemiluminescence (ECL) detection kit (Thermo Scientific, USA). The optical densities of the target proteins in each sample was measured with a gel reader and normalized to β-actin expression. The expression of H3K56ac (A7256, ABclonal, Inc., Woburn, MA, USA) was determined by immunoblotting with H3 (E1A6359; EnoGene Biotech Co. Ltd., Nanjing, China) as the loading control. Assays were performed in triplicate.

Statistical Analysis
Data were reported as means ± SEM and the probability value used for statistical significance was P < 0.05. Statistical analysis was performed with GraphPad Software (San Diego, CA, USA).
Between-group differences in nonparametric data were analyzed by the Mann–Whitney test for two groups and the Kruskall–Wallis test for more than two groups. Differences in continuous data were tested by parametric methods, ANOVA or Student’s *t*-test.

**RESULTS**

**Lung Branching-Associated Factors in the Hypoplastic Lungs**

We previously reported that primary lung maldevelopment caused by deficient airway branching in experimental EA-TEF, and *Fgf10*, a key mesenchymal regulator of the process of endodermal branching was significantly deficient on E21 [10]. Expression of *Fgf10* pathway components in hypoplastic lungs including its specific cell surface receptor (*Fgfr2b*), negative regulator sonic hedgehog (*Shh*), and the downstream targets *Bmp4* and *Ctsh* was assayed. The expression of *Shh*, an epithelial gene known to negatively regulate *Fgf10* expression, was unchanged compared with that in control lungs (Figure 1A), indicating that other distal epithelial signals regulate mesenchymal *Fgf10* expression. No significant differences were observed in the gene expression pattern of receptor *Fgfr2b* and *Bmpr1a*, while *Bmp4* expression tended to be lower at E21 in hypoplastic lung tissue (Figures 1B–D). In the saccular stage, *Ctsh* mRNA was significantly decreased in hypoplastic lungs compared with the controls (Figure 1E), similar to the expression of *Fgf10*. The specificity of primers for *Fgf10* pathway factors

![FIGURE 3](image-url)
was confirmed by agarose gels electrophoresis (Figure 1F). The differences in Bmp4 and Ctsb protein expression indicated by immunoblotting and IHC were consistent with the quantitative PCR results (Figures 2A–D).

**Lung Epithelium-Associated Factors in Hypoplastic Lungs**

To investigate the impairment of the development of fetal lung epithelium by doxorubicin, we determined the expression of genes coding for epithelial cell proteins including purinergic ligand-gated ion channel 7 receptor (P2X7R), an alveolar epithelial type I (ATI) cell marker, surfactant protein (SP)A, Sftpa, Sftpb, alveolar epithelial type II (ATII) markers, and Clara cell secretory protein (SCGB1A1), a, Clara cell marker. Quantitative PCR found that, as gestational age increases, the developmental patterns of P2x7r, Sftpa, and Sftpb, mRNA expression in normal and hypoplastic lungs were similar. P2x7r and Sftpa expression were relatively constant, and Sftpb expression increased from E15 to E18 (Figures 3A–D). In contrast, at E21 Sftpc mRNA level was lower in hypoplastic lungs than in control lungs (Figure 3C). In both group, Scgb1a1 mRNA decreased slightly at E18, and then increased significantly at E21. Like Sftpc, Scgb1a1 expression was downregulated in hypoplastic, compared with control lungs at the saccular stage (Figure 4A). The specificity of primers for lung epithelium-associated factors was confirmed by agarose gels electrophoresis (Figures 3E, 4D). Assay of the spatial and temporal expression of Scgb1a1 protein by IHC found that it was mainly expressed in bronchial epithelial cells. No differences in the localization pattern of Scgb1a1 protein in normal and hypoplastic lungs were observed in the canalicular and saccular stages. At E21, the IHC staining intensity of Scgb1a1 protein decreased in embryos with EA compared with age-matched control (Figures 5A–D). The expression of phospholipase A2 (including intracellular Pla2g4a and secreted Pla2g2a), a key enzyme in pulmonary inflammation and cell injury that is inhibited by Scgb1a1 [18] was unchanged (Figures 4B,C). The spatial expression pattern of Pla2g4a protein was also unchanged between two groups (Figures 5E,F).

**Epigenetic Regulatory Factors in Hypoplastic Lungs**

The epigenetic mechanisms underlying the changes of gene expression in lung tissue were investigated by assaying the transcription of DNA methyltransferase (Dnmt1) and histone deacetylase (Hdac) genes. The specificity of primers for epigenetic regulatory factors was confirmed by agarose gels electrophoresis (Figure 6E). Quantitative PCR did not find differences of Dnmt1, Hdac2, and Hdac5 mRNA expression in normal and EA-TEF lungs (Figures 6A–D). Dnmt1 mRNA expression in both groups was increased at E18. Hdac1, Hdac2, and Hdac5 expression remained relatively constant in control lungs at all three developmental stages and was similar.
in both groups except that Hdac1 mRNA was significantly upregulated in hypoplastic lungs compared with the control lungs at E18. Positive immunoreactivity for Hdac1 was seen in mesenchymal cells, in vascular structures in the mesenchyme, and in the luminal airway epithelium during the canalicular and saccular stages. There were no significant differences concerning protein localization, but epithelial and mesenchymal immunoreactivity were stronger in the EA-TEF model than in the control group at the canalicular stage (E18) (Figures 7A,B) but it restored to normal level at E21 (Figures 7C,D). Comparable changes in Hdac1 protein concentrations were observed in the immunoblotting assays (Figures 7E,F). Hdac1 regulates the acetylation state of histone H3 Lys56 (H3K56), and H3K56ac level was significantly decreased in EA lungs (Figures 7G,H).

**DISCUSSION**

Persistent nonspecific respiratory symptoms are commonly presented in children with EA, including brassy cough, bronchitis, pneumonia, asthma-like symptoms, and bronchial hyperresponsiveness [19–23]. Developmental abnormalities of tracheal structure and innervation or lung hypoplasia may account for sequelae that persist into childhood [3, 7, 24, 25]. We previously reported significant underdevelopment of the lungs in experimental EA because of defective embryonic airway branching. These findings support investigation of the mechanisms that underlie defective lung development in EA-TEF patients.

The genetic program of fetal lung development is a complex, tightly regulated process that is influenced by epigenetic and...
environmental factors during embryogenesis. Ohuchi et al. demonstrated that Fgf10 signaling played a key functional role in early embryonic lung epithelial and endothelial crosstalk during branching morphogenesis [13]. Fgf10 produced by lung mesenchymal cells acts as a chemotactic factor on the adjacent epithelium, and temporal and spatial expression of Fgf-10 determine the patterning of lung epithelial tubes. Fgf10 knockout mice exhibit complete lung agenesis, which illustrate the key role played by of Fgf10 during lung development [26]. Decreased expression of Fgf10 was reported in rodents nitrofen-induced pulmonary hypoplasia, furthermore exogenous Fgf-10 during fetal lung development in mice increased branching of nitrofen-exposed lungs [27]. FGF-10 also reduced in the lung tissue of infants with bronchopulmonary dysplasia [28]. Expression of Bmp4 and CtsH are induced by Fgf10 in the distal lung epithelium during branching [29]. Shh, a negative regulator of Fgf-10 expression, is expressed throughout the epithelium of the developing lung, but most strongly in the distal epithelial tips [30]. This study investigated epithelial Fgf10 receptors and other pathway components during lung development in experimental EA-TEF induced by doxorubicin. Consistent with lung underdevelopment, Bmp4 and CtsH expression were downregulated during the saccular stage. We speculated that decreased Fgf10 expression might have led to the reduction of Bmp4 and CtsH associated with inhibition of the branching of lung epithelium. However, Shh expression was unchanged in the model embryos, indicating that other distal epithelial signals regulated mesenchymal Fgf10 expression.

Fgf10 selectively regulates differentiation of the cell lineages in both the proximal conducting airways and the distal respiratory airways. The alveolar epithelium contains type I and type II alveolar cells; the bronchial epithelium includes Clara cells, ciliated cells, and neuroendocrine cells [31]. Sftpc is synthesized only in, and is a specific marker of type II cells [32], as other surfactant proteins including Sftpa and Sftpb are also synthesized in Clara cells. These surfactants are indispensable for the

---

FIGURE 6 | Effect of doxorubicin on expression epigenetic regulatory factors in fetal lungs. (A–D) Dnmt1, Hdac1, Hdac2, and Hdac5 mRNA expression were determined by quantitative PCR relative to E15. (E) the specificity of the PCR products was confirmed visually on 2% agarose gels. Data are means ± SEM, *P < 0.05, EA-TEF vs. age-matched controls, between group; #P < 0.05, E18 or E21 vs. E15, within group.
Clara cell secretory protein (Ccsp; also known as Scgb1a1, Cc10, and uteroglobin) is secreted by Clara cells into the mucus that covers the bronchial epithelium of the mammalian lung. Because it is abundant in the airway mucus [34], Scgb1a1 has been proposed as a marker of airway epithelial damage [35]. Studies in Scgb1a1-deficient mice have indicated that Scgb1a1 is an endogenous inhibitor of Pla2 in pulmonary inflammation [18, 36]. In this study, Sftpc and Scgb1a1 expression were downregulated in the lungs of doxorubicin treated fetus, suggesting impaired development of lung epithelium as a cause of persistent respiratory symptoms.

Epigenetic regulation of gene expression is important for integrating signaling input and transcriptional output during fetal lung development [37]. HDACs regulate chromatin compaction, and aberrant HDAC expression and activity leads to defective lung development, and has been associated with the severity of COPD disease [38, 39]. Currently, little is known about how doxorubicin affects the epigenetic control
of embryonic lung development in EA models. In this study, enhanced Hdac1 expression in hypoplastic lungs may have resulted in deacetylation of lysine 56 of H3. Decreased H3K56ac levels have been positively correlated with changes in gene expression [40] might result in downregulated expression of epithelial proteins required for normal branching in EA models. Chromatin immunoprecipitation and quantitative PCR would be useful in investigating the contribution of histone modification at specific gene promoters to regulation of gene expression in experimental AE models.

In summary, disturbed molecular signaling in lung morphogenesis involving Fgf10/Ctgf results in impaired airway branching and consequent impairment of epithelial cell development, as evidenced by decreased Sfpcc and Sgb1al expression. Recently, Xin Sun et al reported that Fgf-activated transcription factors, Etv4 and Etv5 control Fgf-Shh feedback loop in lung branching. Possible changes of ETV transcription factor in EA-TEF lungs and its effects on lung development deserved further investigation [41]. Upregulated Hdac1 and decreased H3K56ac may have been responsible for decreased expression of epithelial proteins. The findings invite support for further study of epigenetic regulation and correction of the defective lung development in EA-TEF patients.

**AUTHOR CONTRIBUTIONS**

XL conceived and designed the experiments, and wrote the manuscript. JW and HL performed the biological experiments and analyzed the data. LG managed the animals.

**ACKNOWLEDGMENTS**

This work was supported in part by a grant from the National Natural Science Foundation of China (No: 81571449) and the Outstanding Scientific Fund of Shengjing Hospital (No: 201707).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fped.2018.00109/full#supplementary-material

**Figure S1** | Esophageal and pulmonary anatomy of esophageal atresia rat.

**REFERENCES**

1. Nassar N, Leoncini E, Amar E, Arteaga-Vazquez J, Bakker MK, Bower C, et al. Prevalence of esophageal atresia among 18 international birth defects surveillance programs. Birth Defects Res A Clin Mol Teratol. (2012) 94:893–9. doi: 10.1002/bdra.23067
2. Montedonico S, Díez-Pardo JA, Lassaletta L, Tovar JA. Respiratory malformations associated with esophageal atresia. Cir Pediatr. (1999) 12:61–4.
3. Usui N, Kanata S, Ishikawa S, Sawai T, Okuyama H, Imura K, et al. Anomalies of the tracheobronchial tree in patients with esophageal atresia. J Pediatr Surg. (1996) 31:258–62. doi: 10.1016/S0022-3468(96)90010-X
4. Gatzinsky V, Jonsson L, Ekerljung L, Friberg LG, Wennergren G. Long-term respiratory symptoms following esophageal atresia. Acta Paediatrica. (2011) 100:1222–5. doi: 10.1111/j.1651-2227.2011.02279.x
5. Lilja HE, Wester T. Outcome in neonates with esophageal atresia treated over the last 20 years. Pediatr Surg Int. (2008) 24:531–6. doi: 10.1007/s00383-008-2122-z
6. Chen CY, Tsao PN, Chou HC, Chen SJ, Tsou KL. Esophageal atresia associated with tracheal stenosis and right lung agenesis: report of one case. Acta Paediatr Taiwan (2002) 43:348–50. doi: 10.1097/00202122.0348
7. van Dooren M, Tibboel D, Torfs C. The co-occurrence of congenital diaphragmatic hernia, esophageal atresia/tracheoesophageal fistula, and lung hypoplasia. Birth Defects Res A Clin Mol Teratol. (2005) 73:53–7. doi: 10.1002/bdra.20098
8. Goyal A, Jones MO, Couriel JM, Losty PD. Oesophageal atresia and tracheo-oesophageal fistula. Arch Dis Child Fetal Neonatal Ed. (2006) 91:381–4. doi: 10.1136/adc.2005.086157
9. Burri PH. Structural aspects of postnatal lung development - alveolar formation and growth. Biol Neonate. (2006) 89:313–22. doi: 10.1159/000092868
10. Xiaomei L, Aras-Lopez R, Martinez L, Tovar JA. Lung hypoplasia in rats with esophageal atresia and tracheo-esophageal fistula. Pediatr Res. (2012) 71:235–40. doi: 10.1038/pr.2011.41
11. Fragoso AC, Martinez L, Estevao-Costa J, Tovar JA. Maternal hyperthyroidism increases the prevalence of foregut atresias in fetal rats exposed to adriamycin. Pediatr Surg Int. (2014) 30:151–7. doi: 10.1007/s00383-013-3445-y
12. Bellucci S, Grindley J, Emoto H, Itoh N, Hogan B. Fibroblast growth factor 10 (fG10) and branching morphogenesis in the embryonic mouse lung. Development (1997) 124:4867–78.
13. Ohuchi H, Hori Y, Yamasaki M, Harada H, Sekine K, Kato S, et al. Fgf10 acts as a major ligand for fgfr 2 iiib in mouse multi-organ development. Biochem Biophys Res Commun. (2000) 277:643–9. doi: 10.1006/bbrc.2000.3721
14. Sekine K, Ohuchi H, Fujiiwara M, Yamasaki M, Yoshizawa T, Sato T, et al. Fgf10 is essential for limb and lung formation. Nat Genet. (1999) 21:138–41. doi: 10.1038/50906
15. Hiroshima T, Iwasa Y, Morishita Y. Mechanisms for split localization of Fgf10 expression in early lung development. Dev Dyn. (2009) 238:2813–22. doi: 10.1002/dvdy.22108
16. Liu X, Liu C, Ma T, Jiao Y, Miao J, Gao L. Impaired vegf signaling in lungs with hypoplastic esophageal atresia and effects on branching morphogenesis. Cell Physiol Biochem. (2016) 39:385–94. doi: 10.1159/000445632
17. Towbin H, Stachelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets procedure and some applications. Anal Biochem. (1979) 112:195–203. doi: 10.1016/0003-2697(79)90030-2
18. Shiyu S, Zhiyu L, Mao Y, Lin B, Lijia W, Tianbao Z, et al. Polydatin up-regulates Clara cell secretory protein to suppress phospholipase a2 of lung induced by lps in vivo and in vitro. BMC Cell Biol. (2011) 12:31. doi: 10.1186/1471-2121-12-31
19. Chetcuti P, Phelan PD. Respiratory morbidity after repair of esophageal atresia and tracheo-oesophageal fistula. Arch Dis Child. (1993) 68:167–70. doi: 10.1136/adc.68.2.167
20. Malmstrom K, Lohi J, Lindahl H, Pelkonen A, Kajosaari M, Sarna S, et al. Longitudinal follow-up of bronchial inflammation, respiratory symptoms, and pulmonary function in adolescents after repair of esophageal atresia with tracheoesophageal fistula. J Pediatr. (2008) 153:396–401. doi: 10.1016/j.jped.2008.03.034
21. Rintala RJ, Sistonen S, Pakarinen MP. Outcome of esophageal atresia beyond childhood. Semin Pediatr Surg. (2009) 18:50–6. doi: 10.1053/j.sempedsurg.2008.10.010
22. Sistonen S, Malmborg P, Malmstrom K, Haahlela T, Sarna S, Rintala RJ, et al. Repaired esophageal atresia: respiratory morbidity and pulmonary function in adults. Eur Respir J. (2010) 36:1106–12. doi: 10.1183/09031936.001 3209
23. Delacourt C, de Blic J. Pulmonary outcome of esophageal atresia. J Pediatr Gastroenterol Nutr. (2011) 52:31–32. doi: 10.1097/MPG.0b013e318211609a
24. Xia H, Otten C, Migliazza L, Diez-Pardo JA, Tovar JA. Tracheobronchial malformations in experimental esophageal atresia. J Pediatr Surg. (1999) 34:536–9. doi: 10.1016/S0022-3468(99)90067-2
25. Briganti V, Oriolo L, Buffa V, Garofalo S, Cavallaro S, Calisti A. Tracheomalacia in oesophageal atresia: morphological considerations by endoscopic and ct study. *Eur J Cardiothor Surg.* (2005) 28:11–5. doi: 10.1016/j.ejcts.2005.04.003

26. Acarregui MJ, Penisten ST, Goss KL, Ramirez K, Snyder JM. Vascular endothelial growth factor gene expression in human fetal lung in vitro. *Am J Respir Cell Mol Biol.* (1999) 20:14–23. doi: 10.1165/ajrcmb.20.1.3251

27. Acosta JM, Thebaud B, Castillo C, Mailleux A, Tefft D, Wuenschell C, et al. Novel mechanisms in murine nitrofen-induced pulmonary hypoplasia: Fgf-10 rescue in culture. *Am J Physiol Lung Cell Mol Physiol.* (2001) 281:250–7. doi: 10.1152/ajplung.2001.281.1.L250

28. Benjamin JT, Smith RJ, Halloran BA, Day TJ, Kelly DR, Prince LS. Fgf-10 is decreased in bronchopulmonary dysplasia and suppressed by toll-like receptor activation. *Am J Physiol Lung Cell Mol Physiol.* (2007) 292:550–8. doi: 10.1152/ajplung.00329.2006

29. Lu J, Qian J, Keppler D, Cardoso WV. Cathespin h is an fgf10 target involved in bmp4 degradation during lung branching morphogenesis. *J Biol Chem.* (2007) 282:22176–84. doi: 10.1074/jbc.M700063200

30. Kim N, Yamamoto H, Pauling MH, Lorizio W, Vu TH. Ablation of lung epithelial cells deregulates fgf-10 expression and impairs lung branching morphogenesis. *Anatomical Record.* (2009) 292:123–5. doi: 10.1002/ar.20799

31. Nyeng P, Norgaard GA, Kobberup S, Jensen J. Fgf10 maintains distal lung bud epithelium and excessive signaling leads to progenitor state arrest, distalization, and goblet cell metaplasia. *BMC Dev Biol.* (2008) 8:2. doi: 10.1186/1471-213X-8-2

32. Kondo H, Miyoshi K, Sakiyama S, Tanguok A, Noma T. Differential regulation of gene expression of alveolar epithelial cell markers in human lung adenocarcinoma-derived A549 clones. *Stem Cells Int.* (2015) 2015:165867. doi: 10.1155/2015/165867

33. Rock JR, Hogan BLM. Epithelial progenitor cells in lung development, maintenance, repair, and disease. *Am Rev Respir Cell Dev Biol.* (2011) 27:493–7. doi: 10.1146/annurev-cellbio-100109-104040

34. Reynolds SD, Malkinson AM. Clara cell: progenitor for the broncholar epithelium. *Int J Biochem Cell Biol.* (2010) 42:1–4. doi: 10.1016/j.biocel.2009.09.002

35. Shashikant BN, Miller TL, Welch RW, Pilon AL, Shaffer TH, Wolfson MR. Dose response to rhcc10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. *J Appl Physiol.* (2005) 99:2204–11. doi: 10.1152/japplphysiol.00246.2005

36. Jorens PG, Sibille Y, Goulding NJ, van Overveld FJ, Herman AG, Bossaert L, et al. Potential role of Clara cell protein, an endogenous phospholipase a2 inhibitor, in acute lung injury. *Eur Respir J.* (1995) 8:1647–53. doi: 10.1183/09031936.95.08101647

37. Xu CR, Cole PA, Meyers DJ, Kornish J, Dent S, Zaret KS. Chromatin “pre-pattern” and histone modifiers in a fate choice for liver and pancreas. *Science* (2011) 332:963–6. doi: 10.1126/science.1202845

38. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylation activity in chronic obstructive pulmonary disease. *N Engl J Med.* (2005) 352:1967–76. doi: 10.1056/NEJMoa041892

39. Ito K, Yamamura S, Essilfe-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylation 2-mediated deacetylation of the glucocorticoid receptor enables nf-kappab suppression. *J Exp Med.* (2006) 203:7–13. doi: 10.1084/jem.20050466

40. Dovy OM, Foster CT, Cowley SM. Histone deacetylase 1 (hdac1), but not hdac2, controls embryonic stem cell differentiation. *Proc Natl Acad Sci USA.* (2010) 107:8242–7. doi: 10.1073/pnas.1000478107

41. Herriges JC, Verheyden JM, Zhang Z, Sui P, Zhang Y, Anderson MJ, et al. Fgf-regulated ETV transcription factors control fgf-shh feedback loop in lung branching. *Dev Cell* (2015) 35:322–32. doi: 10.1016/j.devcel.2015.10.006

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2018 Wang, Liu, Gao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*